Eli Lilly axes 163 Dermira staffers, shutters Menlo Park site as it closes in around Dupixent rival lebrikizumab
Eli Lilly made it clear when it shelled out $1.1 billion for Dermira that lebrikizumab is really what it wanted to buy. One year in, the pharma giant is completing its cleavage of the rest.
Days after unveiling the sale of Qbexza — Dermira’s only approved product, a piece of cloth to block excessive sweating — Lilly revealed plans to close down the biotech’s Menlo Park facility, putting 163 jobs on the chopping block. The San Francisco Business Times first reported on the WARN notice filed in early April.